Payment overview · 2025
General Payments
$1,825.49
27 reported records · 16 companies
Healthcare provider profile · identity verified
Daniel Steiner
Allopathic & Osteopathic Physicians|Internal Medicine · OAKMONT, PA · NPI 1700868502
Verified facts
What the public records show
CMS Open Payments records show Daniel Steiner received $1,825.49 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 366 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 366 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.67 | 25.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $184.85 | 10.1% | 5 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $142.07 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.63 | 7.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $129.32 | 7.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $126.60 | 6.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $119.89 | 6.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.20 | 6.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.67 | 6.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $90.00 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.15 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.32 | 2.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.15 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.63 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.50 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.84 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,825.49 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $345.26 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $142.07 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $135.63 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $131.38 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $129.32 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $126.60 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $119.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.41 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $114.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.67 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $90.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $81.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 366 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 189 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 38 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
366 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
366 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1241 | 355 |
| Lisinopril | Lisinopril | 887 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 723 | 203 |
| Levothyroxine Sodium | Levothyroxine Sodium | 693 | 171 |
| Metformin Hcl | Metformin Hcl | 441 | 129 |
| Losartan Potassium | Losartan Potassium | 408 | 113 |
| Eliquis | Apixaban | 366 | 74 |
| Omeprazole | Omeprazole | 363 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 342 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 81 |
| Simvastatin | Simvastatin | 312 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 89 |
| Naproxen | Naproxen | 278 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 252 | 60 |
| Buspirone Hcl | Buspirone Hcl | 246 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 76 |
| Gabapentin | Gabapentin | 217 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 50 |
| Alendronate Sodium | Alendronate Sodium | 191 | 47 |
| Jardiance | Empagliflozin | 189 | 38 |
| Famotidine | Famotidine | 180 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 43 |
| Allopurinol | Allopurinol | 166 | 51 |
| Valsartan | Valsartan | 161 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 37 |
| Trazodone Hcl | Trazodone Hcl | 154 | 43 |
| Warfarin Sodium | Warfarin Sodium | 151 | 19 |
| Sertraline Hcl | Sertraline Hcl | 148 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 40 |
| Furosemide | Furosemide | 145 | 50 |
| Mirtazapine | Mirtazapine | 141 | 28 |
| Montelukast Sodium | Montelukast Sodium | 124 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 122 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 23 |
| Potassium Chloride | Potassium Chloride | 118 | 32 |
| Farxiga | Dapagliflozin Propanediol | 116 | 32 |
| Ozempic | Semaglutide | 115 | 22 |
| Finasteride | Finasteride | 108 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 30 |
| Xarelto | Rivaroxaban | 95 | 23 |
| Synthroid | Levothyroxine Sodium | 94 | 25 |
| Ezetimibe | Ezetimibe | 85 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 83 | 15 |
| Memantine Hcl | Memantine Hcl | 80 | 21 |
| Meloxicam | Meloxicam | 78 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 76 | 11 |
| Donepezil Hcl | Donepezil Hcl | 70 | 24 |
| Atenolol | Atenolol | 69 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 12 |
| Carvedilol | Carvedilol | 66 | 23 |
| Irbesartan | Irbesartan | 65 | 19 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Vascepa | Icosapent Ethyl | 65 | suppressed |
| Rybelsus | Semaglutide | 64 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 56 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 15 |
| Valacyclovir | Valacyclovir Hcl | 51 | 19 |
| Spironolactone | Spironolactone | 49 | 20 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 11 |
| Prednisone | Prednisone | 45 | 28 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 14 |
| Colchicine | Colchicine | 42 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | 17 |
| Lorazepam | Lorazepam | 35 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Indapamide | Indapamide | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Topiramate | Topiramate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Nateglinide | Nateglinide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Invokana | Canagliflozin | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 11 |
| Linzess | Linaclotide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,825.49 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAMZYOS, CeQur Simplicity, ELIQUIS, INGREZZA, INJECTAFER, JARDIANCE, KISUNLA, Leqembi, Ohtuvayre, Ozempic, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error